methyl (S)-5-(α-aminophenethyl)oxazole-4-carboxylate Trifluoroacetate | 403860-29-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (S)-5-(α-aminophenethyl)oxazole-4-carboxylate Trifluoroacetate
• 英文别名: Methyl (s)-5-(1-amino-2-phenylethyl)oxazole-4-carboxylate trifluoroacetate；methyl 5-[(1S)-1-amino-2-phenylethyl]-1,3-oxazole-4-carboxylate;2,2,2-trifluoroacetic acid
• CAS: 403860-29-7
• 化学式: C₂HF₃O₂*C₁₃H₁₄N₂O₃
• 分子量: 360.29
• InChiKey: WFYQUZSACLMPFC-PPHPATTJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.34
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  2-Chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid 、 methyl (S)-5-(α-aminophenethyl)oxazole-4-carboxylate Trifluoroacetate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以34%的产率得到(S)-2-chloro-5-{N-[α-(4-methoxycarbonyloxazol-5-yl)phenethyl]carbamoyl}-6H-thieno[2,3-b]pyrrole
  参考文献：
  名称：

  Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors

  摘要：

  杂环酰胺衍生物的化学式（I）：其中—X-Y-Z-选择自—S—CR4═CR5—，—CR4═CR5—S—，—O—CR4═CR5—，—CR4═CR5—O—，—N═CR4—S—，—S—CR4═N—，—NR6—CR4═CR5—和—CR4═CR5—NR6—；或其药学上可接受的盐或体内可水解酯；（附带条件）；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。

  公开号：

  US20030232875A1
• 作为产物：
  描述：

  methyl (S)-5-[α-(tert-butoxycarbonylamino)phenethyl]-oxazole-4-carboxylate 在 三氟乙酸 作用下， 反应 1.0h， 生成 methyl (S)-5-(α-aminophenethyl)oxazole-4-carboxylate Trifluoroacetate
  参考文献：
  名称：

  Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors

  摘要：

  杂环酰胺衍生物的化学式（I）：其中—X-Y-Z-选择自—S—CR4═CR5—，—CR4═CR5—S—，—O—CR4═CR5—，—CR4═CR5—O—，—N═CR4—S—，—S—CR4═N—，—NR6—CR4═CR5—和—CR4═CR5—NR6—；或其药学上可接受的盐或体内可水解酯；（附带条件）；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。

  公开号：

  US20030232875A1

文献信息

• Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
  申请人：Stocker Andrew

  公开号：US20050130963A1

  公开（公告）日：2005-06-16

  Heterocyclic amides of formula (1) wherein: m is 0, 1 or 2; n is 0, 1 or 2; B is phenyl or heterocyclyl; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R 2 and R 3 are independently selected from, for example, C 5-7 cycloalkyl, cyano(C 1-4 )alkyl, C 1-4 alkyl (optionally substituted with 1 or 2 R 8 groups), OR 8 and R 8 ; R 4 is independently selected from for example hydrogen, halo, nitro, cyano, hydroxy, C 1-4 alkyl, and C 1-4 alkanoyl; R 8 is selected from for example hydroxy, heterocyclyl, aryl, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from for example, hydroxy, C 1-4 alkoxy, heterocyclyl and C 1-4 alkanoyl; R 14 is selected from for example, hydrogen, halo, C 1-4 alkyl, C 5-7 cycloalkyl, C 1-4 alkoxy, cyano, cyano(C 1-4 )alkyl, —COR 3 , (R 2 )(R 3 )NCO—, and (R 2 )(R 3 )NSO 2 —; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  式（1）中的杂环酰胺，其中：m为0、1或2；n为0、1或2；B为苯基或杂环基；R1从卤素、硝基、氰基、羟基、羧基等中选择；R2和R3分别从C5-7环烷基、氰基（C1-4）烷基、C1-4烷基（可选地取代1或2个R8基）、OR8和R8中独立选择；R4从氢、卤素、硝基、氰基、羟基、C1-4烷基和C1-4烷酰基等中独立选择；R8从羟基、杂环基、芳基、—COCOOR9、—C（O）N（R9）（R10）、（R9）（R10）N—和—COOR9等中选择；R9和R10从氢、羟基、C1-4烷基（可选地取代1或2个R13）等中选择；R13从羟基、C1-4烷氧基、杂环基和C1-4烷酰基等中选择；R14从氢、卤素、C1-4烷基、C5-7环烷基、C1-4烷氧基、氰基、氰基（C1-4）烷基、—COR3、（R2）（R3）NCO—和（R2）（R3）NSO2—等中选择；或其药学上可接受的盐或前药。这些化合物具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态方面具有价值。描述了制备上述杂环酰胺衍生物的方法和含有它们的制药组合物。
• INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY
  申请人：Stocker Andrew

  公开号：US20070123528A1

  公开（公告）日：2007-05-31

  Heterocyclic amides of formula (1) and pharmaceutically acceptable salts or pro-drugs thereof wherein variable groups are as described herein; which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity are described. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are also described.

  本文描述了公式（1）的杂环酰胺及其药学上可接受的盐或前药，其中可变基团如本文所述；它们具有糖原磷酸化酶抑制活性，因此在治疗与增加糖原磷酸化酶活性相关的疾病状态方面具有价值。本文还描述了制造这些杂环酰胺衍生物的过程和包含它们的药物组合物。
• Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
  申请人：——

  公开号：US20030232875A1

  公开（公告）日：2003-12-18

  Heterocyclic amide derivatives, of formula (I): wherein —X-Y-Z- is selected from —S—CR 4 ═CR 5 —, —CR 4 ═CR 5 —S—, —O—CR 4 ═CR 5 —, —CR 4 ═CR 5 —O—, —N═CR 4 —S—, —S—CR 4 ═N—, —NR 6 —CR 4 ═CR 5 — and —CR 4 ═CR 5 —NR 6 —; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; (with provisos); possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  杂环酰胺衍生物的化学式（I）：其中—X-Y-Z-选择自—S—CR4═CR5—，—CR4═CR5—S—，—O—CR4═CR5—，—CR4═CR5—O—，—N═CR4—S—，—S—CR4═N—，—NR6—CR4═CR5—和—CR4═CR5—NR6—；或其药学上可接受的盐或体内可水解酯；（附带条件）；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。